1. EMA, European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP),Paediatric Committee (PDCO), Guideline on pharmaceutical development of medicines for pediatric use (CHMP/QWP/180157/2011) [Online], Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/07/WC500147002.pdf (2011).
2. WHO, World Health Organisation, Revised WHO Classification and Treatment of Pneumonia in Children at Health Facilities: Evidence Summaries. Geneva: World Health Organization; 3, Flexible Solid Oral Dosage: Dispersible formulations of amoxicillin. Available from: https://www.ncbi.nlm.nih.gov/books/NBK264163/, (2014).
3. N.V. Kalepu S, Insoluble drug delivery strategies: review of recent advances and business prospects., Acta Pharm Sin B., 5 (2015) 442-453.
4. PharmaCircle: Water Insoluble Drug Development: Strategies, Technologies, Case Studies Available at https://www.pharmacircle.com/presentations/Water_Insoluble_Strategies.pdf (2011).
5. V.J.N.-A. Stella, K. W, Prodrug strategies to overcome poor water solubility., AdV. Drug DeliVery ReV., 59 (2007) 677-694.